drugset / Trial / NCT05893043
A Study of Multiple Ascending Doses of GSBR-1290 in Japanese and Non-Japanese Healthy Participants
Phase 1
Completed
18 enrolled
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to assess safety and tolerability of multiple oral doses of GSBR-1290 (capsule) in healthy adult Japanese participants compared to non-Japanese participants.
Timeline
- Start
- 2023-04-24
- Primary completion
- 2023-06-28
- Completion
- 2023-06-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aleniglipron | Small molecule | — | Oral |
Indications
No indication recorded.